Showing 741-750 of 753 results for "".
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at the American Academy of Dermatology Annual Meeting i…
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment …
Scientifically Speaking: Applying Energy-Based Devices Across Skin Tones
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-applying-energy-based-devices-across-skin-tones/19895/With advancements in technology and a patient-focused approach to treatment, it's possible to safely and effectively apply energy-based devices to a range of skin concerns in patients with darker skin. Host Joel L. Cohen, MD discusses treatment strategies for melasma, acne, PFB, scarring and more wiClosing Gaps in Care for People of Color with Psoriatic Disease
https://practicaldermatology.com/series/the-practical-dermatology-podcast/closing-gaps-in-care-for-people-of-color-with-psoriatic-disease/18190/Black, Hispanic, Asian, and other people of color with plaque psoriasis and psoriatic arthritis often face delayed diagnosis, misdiagnosis, and limited access to testing, treatment, and care. Determi-Nation, a new initiative sponsored by Janssen Pharmaceuticals, aims to change this. Patient advocateSeparating Fact from Fiction: The Realities of CKD-aP
https://practicaldermatology.com/programs/cme/separating-fact-from-fiction-the-realities-of-ckd-ap/14964/Separate facts from fiction in CKD-aP! Our experts tackle this often overlooked condition and discuss ways to improve your patients’ lives.Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
https://practicaldermatology.com/programs/cme/pruritus-cases-from-the-field-real-world-perspectives-on-managing-ckd-ap/14969/Did you know that many patients on dialysis suffer from itch, or pruritus? Hear patients describe their experiences with a new FDA-approved therapy.Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes
https://practicaldermatology.com/programs/cme/targeting-il-13-in-moderate-to-severe-atopic-dermatitis-forging-a-new-path-to-improved-disease-and-patient-outcomes/16384/Get expert insights on incorporating novel agents to optimize care for patients with atopic dermatitis, including those targeting interleukin (IL)-13.Directed Relief in CKD-aP: Linking Targeted Therapy to Clinical Outcomes
https://practicaldermatology.com/programs/cme/directed-relief-in-ckd-ap-linking-targeted-therapy-to-clinical-outcomes/14967/Join our experts’ discussion to learn how to significantly improve quality of life for your patients with chronic kidney disease-associated pruritus.Pipeline Watch: Sizing Up a Promising Phase III IL-17 Biologic
https://practicaldermatology.com/topics/psoriasis/pipeline-watch-sizing-up-a-promising-phase-iii-il-17-biologic/21214/Pipeline Watch is a new Q&A feature appearing periodically in Practical Dermatology® that explores the potential of therapeutic agents currently under investigation. In each edition, we will speak with investigators from manufacturing companies to gain insights about the development and investig